Influenza is typically a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1). Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated with influenza illness. Annual vaccination should be offered to all persons ≥6 months old as long as influenza viruses are circulating in the community.1
TREATMENT OF INFLUENZA — Antiviral treatment is recommended as...
RELEASE
The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes. Reducing UACR is expected to reduce the risk of sustained eGFR decline and progression to end-stage kidney disease. Finerenone is the first drug to be approved in the US for this indication in 30 years.
OTHER INDICATIONS — Finerenone is also FDA-approved to reduce the risk of kidney disease progression and cardiovascular events in adults with CKD associated with type 2 diabetes and to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adults with HF with a left ventricular ejection fraction (LVEF) ≥40%.1,2
MECHANISM OF ACTION — CKD and cardiovascular disease are common complications of type 1 …